Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
25,125
archived clinical trials in
Diabetes

Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  3/4/2016
Clinical Research Facility
mi
from
Palm Springs, CA
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 3/4/2016
Clinical Research Facility
mi
from
Palm Springs, CA
Click here to add this to my saved trials
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  3/4/2016
Clinical Research Facility
mi
from
Pismo Beach, CA
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 3/4/2016
Clinical Research Facility
mi
from
Pismo Beach, CA
Click here to add this to my saved trials
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  3/4/2016
Clinical Research Facility
mi
from
Boynton Beach, FL
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 3/4/2016
Clinical Research Facility
mi
from
Boynton Beach, FL
Click here to add this to my saved trials
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  3/4/2016
Clinical Research Facility
mi
from
Bradenton, FL
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 3/4/2016
Clinical Research Facility
mi
from
Bradenton, FL
Click here to add this to my saved trials
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  3/4/2016
Clinical Research Facility
mi
from
Coral Gables, FL
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 3/4/2016
Clinical Research Facility
mi
from
Coral Gables, FL
Click here to add this to my saved trials
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  3/4/2016
Clinical Research Facility
mi
from
Hialeah, FL
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 3/4/2016
Clinical Research Facility
mi
from
Hialeah, FL
Click here to add this to my saved trials
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  3/4/2016
Clinical Research Facility
mi
from
Largo, FL
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 3/4/2016
Clinical Research Facility
mi
from
Largo, FL
Click here to add this to my saved trials
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  3/4/2016
Clinical Research Facility
mi
from
New Port Richey, FL
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 3/4/2016
Clinical Research Facility
mi
from
New Port Richey, FL
Click here to add this to my saved trials
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  3/4/2016
Clinical Research Facility
mi
from
Orlando, FL
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 3/4/2016
Clinical Research Facility
mi
from
Orlando, FL
Click here to add this to my saved trials
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  3/4/2016
Clinical Research Facility
mi
from
Pembroke Pines, FL
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 3/4/2016
Clinical Research Facility
mi
from
Pembroke Pines, FL
Click here to add this to my saved trials
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  3/4/2016
Clinical Research Facility
mi
from
Decatur, GA
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 3/4/2016
Clinical Research Facility
mi
from
Decatur, GA
Click here to add this to my saved trials
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  3/4/2016
Clinical Research Facility
mi
from
Chicago, IL
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 3/4/2016
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  3/4/2016
Clinical Research Facility
mi
from
Avon, IN
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 3/4/2016
Clinical Research Facility
mi
from
Avon, IN
Click here to add this to my saved trials
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  3/4/2016
Clinical Research Facility
mi
from
Greenfield, IN
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 3/4/2016
Clinical Research Facility
mi
from
Greenfield, IN
Click here to add this to my saved trials
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  3/4/2016
Clinical Research Facility
mi
from
Muncie, IN
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 3/4/2016
Clinical Research Facility
mi
from
Muncie, IN
Click here to add this to my saved trials
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  3/4/2016
Clinical Research Facility
mi
from
Council Bluffs, IA
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 3/4/2016
Clinical Research Facility
mi
from
Council Bluffs, IA
Click here to add this to my saved trials
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  3/4/2016
Clinical Research Facility
mi
from
Topeka, KA
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 3/4/2016
Clinical Research Facility
mi
from
Topeka, KA
Click here to add this to my saved trials
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  3/4/2016
Clinical Research Facility
mi
from
Lexington, KY
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 3/4/2016
Clinical Research Facility
mi
from
Lexington, KY
Click here to add this to my saved trials
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  3/4/2016
Clinical Research Facility
mi
from
Oxon Hill, MD
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 3/4/2016
Clinical Research Facility
mi
from
Oxon Hill, MD
Click here to add this to my saved trials
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  3/4/2016
Clinical Research Facility
mi
from
Flint, MI
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 3/4/2016
Clinical Research Facility
mi
from
Flint, MI
Click here to add this to my saved trials
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  3/4/2016
Clinical Research Facility
mi
from
Picayune, MS
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 3/4/2016
Clinical Research Facility
mi
from
Picayune, MS
Click here to add this to my saved trials
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  3/4/2016
Clinical Research Facility
mi
from
Omaha, NE
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 3/4/2016
Clinical Research Facility
mi
from
Omaha, NE
Click here to add this to my saved trials
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  3/4/2016
Clinical Research Facility
mi
from
Elizabeth, NJ
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 3/4/2016
Clinical Research Facility
mi
from
Elizabeth, NJ
Click here to add this to my saved trials
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  3/4/2016
Clinical Research Facility
mi
from
Charlotte, NC
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 3/4/2016
Clinical Research Facility
mi
from
Charlotte, NC
Click here to add this to my saved trials
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  3/4/2016
Clinical Research Facility
mi
from
Greensboro, NC
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 3/4/2016
Clinical Research Facility
mi
from
Greensboro, NC
Click here to add this to my saved trials
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  3/4/2016
Clinical Research Facility
mi
from
Mooresville, NC
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 3/4/2016
Clinical Research Facility
mi
from
Mooresville, NC
Click here to add this to my saved trials
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  3/4/2016
Clinical Research Facility
mi
from
Morganton, NC
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 3/4/2016
Clinical Research Facility
mi
from
Morganton, NC
Click here to add this to my saved trials
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  3/4/2016
Clinical Research Facility
mi
from
Raleigh, NC
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 3/4/2016
Clinical Research Facility
mi
from
Raleigh, NC
Click here to add this to my saved trials
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  3/4/2016
Clinical Research Facility
mi
from
Maumee, OH
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 3/4/2016
Clinical Research Facility
mi
from
Maumee, OH
Click here to add this to my saved trials
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  3/4/2016
Clinical Research Facility
mi
from
Oklahoma City, OK
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 3/4/2016
Clinical Research Facility
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  3/4/2016
Clinical Research Facility
mi
from
Harleysville, PA
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 3/4/2016
Clinical Research Facility
mi
from
Harleysville, PA
Click here to add this to my saved trials
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  3/4/2016
Clinical Research Facility
mi
from
Levittown, PA
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 3/4/2016
Clinical Research Facility
mi
from
Levittown, PA
Click here to add this to my saved trials
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  3/4/2016
Clinical Research Facility
mi
from
Uniontown, PA
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 3/4/2016
Clinical Research Facility
mi
from
Uniontown, PA
Click here to add this to my saved trials
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  3/4/2016
Clinical Research Facility
mi
from
Greer, SC
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 3/4/2016
Clinical Research Facility
mi
from
Greer, SC
Click here to add this to my saved trials
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  3/4/2016
Clinical Research Facility
mi
from
Crossville, TN
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 3/4/2016
Clinical Research Facility
mi
from
Crossville, TN
Click here to add this to my saved trials
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  3/4/2016
Clinical Research Facility
mi
from
Carrollton, TX
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 3/4/2016
Clinical Research Facility
mi
from
Carrollton, TX
Click here to add this to my saved trials
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  3/4/2016
Clinical Research Facility
mi
from
Dallas, TX
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 3/4/2016
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  3/4/2016
Clinical Research Facility
mi
from
El Pasco, TX
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 3/4/2016
Clinical Research Facility
mi
from
El Pasco, TX
Click here to add this to my saved trials
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  3/4/2016
Clinical Research Facility
mi
from
Fort Worth, TX
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 3/4/2016
Clinical Research Facility
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  3/4/2016
Clinical Research Facility
mi
from
Ft. Worth, TX
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 3/4/2016
Clinical Research Facility
mi
from
Ft. Worth, TX
Click here to add this to my saved trials
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  3/4/2016
Clinical Research Facility
mi
from
Houston, TX
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 3/4/2016
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  3/4/2016
Clinical Research Facility
mi
from
Irving, TX
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 3/4/2016
Clinical Research Facility
mi
from
Irving, TX
Click here to add this to my saved trials
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  3/4/2016
Clinical Research Facility
mi
from
New Braunfels, TX
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 3/4/2016
Clinical Research Facility
mi
from
New Braunfels, TX
Click here to add this to my saved trials
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  3/4/2016
Clinical Research Facility
mi
from
San Antonio, TX
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 3/4/2016
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  3/4/2016
Clinical Research Facility
mi
from
Spring, TX
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 3/4/2016
Clinical Research Facility
mi
from
Spring, TX
Click here to add this to my saved trials
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  3/4/2016
Clinical Research Facility
mi
from
Tomball, TX
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 3/4/2016
Clinical Research Facility
mi
from
Tomball, TX
Click here to add this to my saved trials
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  3/4/2016
Clinical Research Facility
mi
from
Salt Lake City, UT
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 3/4/2016
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  3/4/2016
Clinical Research Facility
mi
from
Burke, VA
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 3/4/2016
Clinical Research Facility
mi
from
Burke, VA
Click here to add this to my saved trials
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  3/4/2016
Clinical Research Facility
mi
from
Manassas, VA
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 3/4/2016
Clinical Research Facility
mi
from
Manassas, VA
Click here to add this to my saved trials
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  3/4/2016
Clinical Research Facility
mi
from
Goodyear, AZ
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 3/4/2016
Clinical Research Facility
mi
from
Goodyear, AZ
Click here to add this to my saved trials